2015 - Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases, American Academy of Neurology
2015 - Sedgwick Memorial Medal, American Public Health Association
Reisa A. Sperling spends much of his time researching Alzheimer's disease, Neuroscience, Dementia, Disease and Cognition. His Alzheimer's disease research is multidisciplinary, incorporating elements of Biomarker, Neuroimaging and Cognitive decline. His Dementia research is multidisciplinary, incorporating perspectives in Gerontology, Predictive value of tests, Age of onset, PSEN1 and Amyloid.
His studies in Disease integrate themes in fields like Psychiatry, Clinical trial, Bioinformatics and Intensive care medicine. Reisa A. Sperling focuses mostly in the field of Cognition, narrowing it down to topics relating to Cohort study and, in certain cases, Executive dysfunction and Activities of daily living. His research integrates issues of Placebo and Oncology in his study of Internal medicine.
His main research concerns Disease, Neuroscience, Internal medicine, Alzheimer's disease and Dementia. His study focuses on the intersection of Disease and fields such as Cognition with connections in the field of Clinical psychology, Audiology and Developmental psychology. As a member of one scientific family, Reisa A. Sperling mostly works in the field of Neuroscience, focusing on Amyloid and, on occasion, Positron emission tomography.
His biological study spans a wide range of topics, including Endocrinology and Oncology. His Alzheimer's disease research includes themes of Magnetic resonance imaging and Neuroimaging. His research in Dementia focuses on subjects like Gerontology, which are connected to Activities of daily living.
The scientist’s investigation covers issues in Disease, Internal medicine, Cognitive decline, Cognition and Amyloid. His work in Disease addresses subjects such as Neurology, which are connected to disciplines such as Audiology. His Internal medicine research focuses on subjects like Oncology, which are linked to Biomarker and Positron emission tomography.
His Cognitive decline research entails a greater understanding of Dementia. Anxiety is closely connected to Depression in his research, which is encompassed under the umbrella topic of Cognition. His Amyloid study also includes fields such as
His scientific interests lie mostly in Internal medicine, Alzheimer's disease, Dementia, Cognitive decline and Cognition. His study in the fields of Apolipoprotein E, Family history and Amyloid deposition under the domain of Internal medicine overlaps with other disciplines such as Preliminary analysis. Alzheimer's disease is a subfield of Pathology that he studies.
His Dementia study incorporates themes from Temporal lobe, Asymptomatic, Entorhinal cortex, Pediatrics and Tauopathy. His Cognitive decline research includes elements of Alzheimer's Disease Neuroimaging Initiative, Aging brain and Pittsburgh compound B, Amyloid. His Cognition study integrates concerns from other disciplines, such as Disease, Cohort and Depression.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling;Paul S. Aisen;Laurel A. Beckett;David A. Bennett.
Alzheimers & Dementia (2011)
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease
Randall J. Bateman;Chengjie Xiong;Tammie L.S. Benzinger;Anne M. Fagan.
The New England Journal of Medicine (2012)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack;David A. Bennett;Kaj Blennow;Maria C. Carrillo.
Alzheimers & Dementia (2018)
Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease
Randy L. Buckner;Jorge Sepulcre;Tanveer Talukdar;Fenna M. Krienen.
The Journal of Neuroscience (2009)
Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Clifford R. Jack;Marilyn S. Albert;David S. Knopman;Guy M. McKhann.
Alzheimers & Dementia (2011)
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway;Reisa Sperling;Nick C. Fox;Kaj Blennow.
The New England Journal of Medicine (2014)
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
Frank Jessen;Frank Jessen;Rebecca E. Amariglio;Martin van Boxtel;Monique Breteler.
Alzheimers & Dementia (2014)
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Bengt Winblad;Bengt Winblad;Philippe Amouyel;Sandrine Andrieu;Clive Ballard.
Lancet Neurology (2016)
Amyloid deposition is associated with impaired default network function in older persons without dementia
Reisa A. Sperling;Reisa A. Sperling;Peter S. LaViolette;Kelly O'Keefe;Jacqueline O'Brien.
The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals
Bradford C. Dickerson;Akram Bakkour;David H. Salat;Eric Feczko.
Cerebral Cortex (2009)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: